Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.
Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.
复制标题
DOI：
10.3389/fmed.2021.707104
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Bombardieri M
中科院分区：
文献类型：
--
作者：
Chowdhury F;Tappuni A;Bombardieri M
Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease. It is the second most common rheumatic autoimmune disorder, affecting 0.7% of European Americans and up to 1% of people globally. pSS is characterized by the impaired secretory function of exocrine glands, including salivary and lachrymal glands. A lymphocytic infiltration of these organs leads to the common and debilitating symptoms of oral and ocular dryness, majorly affecting the quality of life of these patients. Currently, no disease-modifying drug has been approved for the treatment of pSS, with therapies largely aimed at relieving symptoms of dry mouth and dry eyes. In particular, management of oral dryness still represents a major unmet clinical need in pSS and a significant burden for patients with this condition. Recently, several randomized clinical trials in pSS with biological therapies targeting specific mechanistic pathways implicated in the disease pathogenesis, including B-cell hyperactivity, T-cell co-stimulation and the aberrant role of cytokines, have been completed with mixed results. In this review, we summarize evidence from recent clinical trials investigating biological therapy in pSS, specifically highlighting efficacy, or lack thereof, in modulating local inflammation and improving salivary gland function.
